Related Experiment Videos
Does nimesulide induce gastric mucosal damage? "A double-blind randomized placebo-controlled trial"
S Kapicioglu1, A H Baki, M Sari
1Black Sea Technical University, School of Medicine, Department of Internal Medicine, Trabzon, Turkey.
Hepato-Gastroenterology
|October 6, 2000
Summary
Nimesulide, a selective COX-2 inhibitor, causes significant gastric mucosal lesions compared to placebo. While less severe than aspirin, nimesulide requires careful administration due to potential gastric damage.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Investigating the gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs) is crucial.
- Selective COX-2 inhibitors are designed to reduce gastrointestinal side effects compared to non-selective NSAIDs.
Purpose of the Study:
- To evaluate the impact of nimesulide, a selective COX-2 inhibitor, on gastric mucosa.
- To compare the gastric mucosal effects of nimesulide with aspirin.
Main Methods:
- A double-blind, randomized, placebo-controlled study involving 32 volunteers.
- Participants received placebo, aspirin (500 mg), or nimesulide (100 mg).
- Gastroduodenoscopy was performed 3 hours post-administration to assess gastric lesions.
Main Results:
- Both aspirin and nimesulide groups showed significantly higher gastric lesion scores compared to placebo (P < 0.00002 and P < 0.01, respectively).
- Nimesulide group had a lower lesion score (1.41 +/- 0.51) than the aspirin group (2.8 +/- 0.46).
- Helicobacter pylori positivity rates were similar across all groups (67-72%) with no statistical difference.
Conclusions:
- Nimesulide induces significant gastric mucosal lesions, comparable to placebo.
- The gastric lesion severity induced by nimesulide is less than that of aspirin.
- Caution is advised when prescribing nimesulide, similar to other analgesics, due to its potential for causing gastric lesions.